Quantrx Biomedical (Quantrx Biomedical) EPS (Basic) : $-0.01 (TTM As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical EPS (Basic)?

Quantrx Biomedical's basic earnings per share (Basic EPS) for the three months ended in Sep. 2022 was $-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.01.

Quantrx Biomedical's EPS (Diluted) for the three months ended in Sep. 2022 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.01.

Quantrx Biomedical's EPS without NRI for the three months ended in Sep. 2022 was $-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2022 was -0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Quantrx Biomedical EPS (Basic) Historical Data

The historical data trend for Quantrx Biomedical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical EPS (Basic) Chart

Quantrx Biomedical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Basic)

Get a 7-Day Free Trial

0.01

-0.01

Quantrx Biomedical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EPS (Basic)	Get a 7-Day Free Trial															-	-0.01	-	-	-

Quantrx Biomedical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Quantrx Biomedical's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.26	-	0)	/	78.696
	=	-0.00

Quantrx Biomedical's Basic EPS for the quarter that ended in Sep. 2022 is calculated as

Basic EPS (Q: Sep. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.061	-	0)	/	78.696
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

Quantrx Biomedical (OTCPK:QTXB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Quantrx Biomedical EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantrx Biomedical (Quantrx Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

10190 SW 90th Avenue, Tualatin, OR, USA, 97062

Website

http://www.quantrx.com

Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.

Executives

Michael S Abrams	director	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney	director	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco	director	1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk	10 percent owner	229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine	director, 10 percent owner	1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr	director	C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton	officer: V.P. of Diagnostics	209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev	officer: Officer	120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman	officer: Officer	5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming	director, officer: Secretary
Walter W Witoshkin	director, officer: President and CEO	321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc	10 percent owner	5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc	10 percent owner	570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines